BiotechTube

VX-407 + Placebo

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Conditions

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Trial Timeline

Jun 12, 2025 → Mar 3, 2026

NCT ID
NCT07022119

About VX-407 + Placebo

VX-407 + Placebo is a phase 1 stage product being developed by Vertex Pharmaceuticals for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The current trial status is active. This product is registered under clinical trial identifier NCT07022119. Target conditions include Autosomal Dominant Polycystic Kidney Disease (ADPKD).

What happened to similar drugs?

1 of 5 similar drugs in Autosomal Dominant Polycystic Kidney Disease (ADPKD) were approved

Approved (1) Terminated (2) Active (2)
✅Placebo + EverolimusNovartisApproved
🔄Everolimus + Calcineurin inhibitors maintenanceNovartisPhase 3
❌Bardoxolone methyl oral capsule + Placebo oral capsuleBiogenPhase 3
🔄Lanreotide + salineIpsenPhase 3
❌Lixivaptan + PlaceboCentessa PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07022119Phase 1Active

Competing Products

19 competing products in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

See all competitors
ProductCompanyStageHype Score
ABBV-CLS-628 + PlaceboAbbViePhase 2
42
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part BAstraZenecaPhase 1
36
Placebo + EverolimusNovartisApproved
43
Octreotide + PlaceboNovartisPhase 2/3
38
Everolimus + Calcineurin inhibitors maintenanceNovartisPhase 3
40
Bosutinib + Bosutinib + PlaceboPfizerPhase 2
35
VX-407Vertex PharmaceuticalsPhase 2
42
VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EEVertex PharmaceuticalsPhase 1
33
VX-407 + Placebo + Midazolam + VX-407Vertex PharmaceuticalsPhase 1
29
TesevatinibSanofiPhase 1/2
32
Tesevatinib + PlaceboSanofiPhase 2
35
Venglustat + PlaceboSanofiPhase 2/3
30
Bardoxolone methyl oral capsule + Placebo oral capsuleBiogenPhase 3
29
Lanreotide + salineIpsenPhase 3
37
KB105Krystal BiotechPhase 2
28
KB105Krystal BiotechPhase 1/2
25
Lixivaptan + PlaceboCentessa PharmaceuticalsPhase 3
29
GLPG2737 + PlaceboGalapagosPhase 2
21
QR-1123ProQRPhase 1/2
26